Back
Rate this talk
Your peers have not rated this talk yet.
16-minute watch | Talk 2 of 3

EBMT: How has CAR T changed the 2L DLBCL treatment landscape?

How has CAR T changed the 2L DLBCL treatment landscape?

Dr Miguel-Angel Perales
SYMPOSIUM
EBMT

Dr Miguel-Angel Perales
Memorial Sloan Kettering Cancer Center, New York, USA

Dr Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center, New York, USA, explores how CAR T-cell therapy has changed the R/R DLBCL treatment landscape, reporting findings from Phase 3 clinical trials such as ZUMA-7 and TRANSFORM

Read more

Talks in this series

Dr Eva Wagner-Drouet and Dr Miguel-Angel Perales present at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
1-minute watch | Talk 1 of 3
EBMT: How has CAR T changed the 2L DLBCL treatment landscape?
Series trailer
Dr Eva Wagner-Drouet and Dr Miguel-Angel Perales present at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
1-minute watch
EBMT: How has CAR T changed the 2L DLBCL treatment landscape?

Series trailer

Dr Miguel-Angel Perales presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
16-minute watch | Talk 2 of 3
How has CAR T changed the 2L DLBCL treatment landscape?
Dr Miguel-Angel Perales
Dr Miguel-Angel Perales presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
16-minute watch

How has CAR T changed the 2L DLBCL treatment landscape?

Dr Miguel-Angel Perales

Dr Eva Wagner-Drouet presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
5-minute watch | Talk 3 of 3
Redefining the treatment paradigm in 2L DLBCL
Dr Eva Wagner-Drouet
Dr Eva Wagner-Drouet presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
5-minute watch

Redefining the treatment paradigm in 2L DLBCL

Dr Eva Wagner-Drouet

Dr Eva Wagner-Drouet and Dr Miguel-Angel Perales present at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
1-minute watch | Talk 1 of 3
EBMT: How has CAR T changed the 2L DLBCL treatment landscape?
Series trailer
Dr Eva Wagner-Drouet and Dr Miguel-Angel Perales present at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
1-minute watch
EBMT: How has CAR T changed the 2L DLBCL treatment landscape?

Series trailer

Dr Miguel-Angel Perales presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
16-minute watch | Talk 2 of 3
How has CAR T changed the 2L DLBCL treatment landscape?
Dr Miguel-Angel Perales
Dr Miguel-Angel Perales presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
16-minute watch

How has CAR T changed the 2L DLBCL treatment landscape?

Dr Miguel-Angel Perales

Dr Eva Wagner-Drouet presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
5-minute watch | Talk 3 of 3
Redefining the treatment paradigm in 2L DLBCL
Dr Eva Wagner-Drouet
Dr Eva Wagner-Drouet presents at EBMT (How has CAR T changed the 2L DLBCL treatment landscape)
5-minute watch

Redefining the treatment paradigm in 2L DLBCL

Dr Eva Wagner-Drouet

Interested in this topic?

Find more like this

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In the United Kingdom, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.